Evins 2005.

Methods	BUPROPION Randomized controlled trial Setting: clinic, USA Recruitment: volunteers
Participants	56 smokers with schizophrenia (>=10 CPD) (excl 6 drop‐outs prior to medication); 27% F, av age 45, av CPD 37/26
Interventions	1. Bupropion 300 mg/day for 3m. 2. Placebo Both arms: 12 session group CBT
Outcomes	Abstinence at 6m (7 day PP) Validation: CO < 9 ppm
Notes	There was a significant treatment effect at EOT. Originally included as Evins 2003 based on abstracts Funding: National Association for Research on Schizophrenia and Affective Disorders. Medication provided by GlaxoSmithKline.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not stated.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Double‐blind" with "identical placebo tablets." No further information provided.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only people taking at least one dose of study medication included in analyses in paper. 5 in each group lost to follow‐up and included as smokers.